Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading candidate ILB-202.
The announcement comes on the 30th Anniversary of the ABE program, which has successfully delivered hands on biotechnology labs to nearly 850,000 students.
Day One Biopharmaceuticals emerged in May to develop new drugs specifically for children with cancer. Now, as it ramps up its work, the company is making a flurry of new hires and new board ...
As a provider of one-stop solution for early-stage drug projects, the New York-based company Protheragen recently announced to launch intermediary services, one of its most distinctive ...
Impact Analysis of Covid-19The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the ...
AQILION AB and Immunscape AB initiated a joint early project in oncology and autoimmune diseases in the spring of 2019. The point of departure was to create a drug candidate that the ...
Yes! Give Me Access to the Videos NowEnter your email below to get instant access to video 1 in our FREE training seriesE-MailSave My Seat NowStart NowWe process your personal data as ...
DGAP-News: Formycon AG / Key word(s): Half Year Results/Miscellaneous23.09.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Press Release // ...